Contrast-enhanced digital breast tomosythesis and breast MRI to monitor response to neoadjuvant chemotherapy: patient tolerance and preference

被引:1
|
作者
Savaridas, Sarah L. [1 ]
Whelehan, Patsy [1 ]
Warwick, Violet R. [1 ]
Vinnicombe, Sarah J. [1 ,2 ]
Evans, Andrew J. [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Sch Med, Dundee, Scotland
[2] Gloucestershire Hosp NHS Fdn Trust, Cheltenham, England
来源
BRITISH JOURNAL OF RADIOLOGY | 2022年 / 95卷 / 1134期
关键词
SPECTRAL MAMMOGRAPHY CESM; CANCER;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective: Contrast-enhanced digital breast tomosynthesis (CE-DBT) is a novel imaging technique, combining contrast-enhanced spectral mammography and tomosynthesis. This may offer an alternative imaging technique to breast MRI for monitoring of response to neoadjuvant chemotherapy. This paper addresses patient experience and preference regarding the two techniques.Methods: Conducted as part of a prospective pilot study; patients were asked to complete questionnaires pertaining to their experience of CE-DBT and MRI following pre-treatment and end-of-treatment imaging. Questionnaires consisted of eight questions answered on a categorical scale, two using a visual analogue scale (VAS), and a question to indicate preference of imaging technique. Statistical analysis was performed with Wilcoxon signed rank test and McNemar test for related samples using SPSS v. 25.Results: 18 patients were enrolled in the pilot study. Matched CE-DBT and MRI questionnaires were completed after 22 patient episodes. Patient preference was indicated after 31 patient episodes. Overall, on 77% of occasions patients preferred CE-DBT with no difference between pre-treatment and end-of-treatment imaging. Overall experience (p = 0.008), non-breast pain (p = 0.046), anxiety measured using VAS (p = 0.003), and feeling of being put at ease by staff (p = 0.023) was better for CE-DBT. However, more breast pain was experienced during CE-DBT when measured on both VAS (p = 0.011) and categorical scale (p = 0.021).Conclusion: Our paper suggests that patients prefer CE-DBT to MRI, adding further evidence in favour of contrast-enhanced mammographic techniques.Advances in knowledge: Contrast mammographic techniques offer an alternative, more accessible imaging technique to breast MRI. Whilst other studies have addressed patient experience of contrast-enhanced spectral mammography, this is the first study to directly explore patient preference for CE-DBT over MRI in the setting of neoadjuvant chemotherapy, finding that overall, patients preferred CE-DBT despite the relatively long breast compression.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Valuation of multi-functional dynamic contrast-enhanced MRI to predict response to neoadjuvant chemotherapy in primary breast cancer
    Ah-See, MLW
    Taylor, NJ
    Makris, A
    Burcombe, RJ
    Stirling, JJ
    Cladd, HJ
    Leach, MO
    Padhani, AR
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 : S41 - S41
  • [22] Effects of contrast-enhanced ultrasound treatment on neoadjuvant chemotherapy in breast cancer
    Rix, Anne
    Piepenbrock, Marion
    Flege, Barbara
    von Stillfried, Saskia
    Koczera, Patrick
    Opacic, Tatjana
    Simons, Nina
    Boor, Peter
    Thoroe-Boveleth, Sven
    Deckers, Roel
    May, Jan-Niklas
    Lammers, Twan
    Schmitz, Georg
    Stickeler, Elmar
    Kiessling, Fabian
    [J]. THERANOSTICS, 2021, 11 (19): : 9557 - 9570
  • [23] Early Response Assessed by Contrast-Enhanced Ultrasound in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
    Dong, Ting
    [J]. ULTRASOUND QUARTERLY, 2018, 34 (02) : 84 - 87
  • [24] Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer
    Fu, Juzhong
    Fan, Ming
    Zheng, Bin
    Shao, Guoliang
    Zhang, Juan
    Li, Lihua
    [J]. MEDICAL IMAGING 2016: PACS AND IMAGING INFORMATICS: NEXT GENERATION AND INNOVATIONS, 2016, 9789
  • [25] Meta-Analysis of Quantitative Dynamic Contrast-Enhanced MRI for the Assessment of Neoadjuvant Chemotherapy in Breast Cancer
    Wei Ju
    Wang Cong
    Xie Xianxi
    Jiang Daqin
    [J]. AMERICAN SURGEON, 2019, 85 (06) : 645 - 653
  • [26] Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
    Eom, Hye-Joung
    Cha, Joo Hee
    Choi, Woo Jung
    Chae, Eun Young
    Shin, Hee Jung
    Kim, Hak Hee
    [J]. AMERICAN JOURNAL OF ROENTGENOLOGY, 2017, 208 (06) : W225 - W230
  • [27] Observer variability in dynamic contrast-enhanced MRI when used for prediction of response to neoadjuvant chemotherapy in primary breast cancer.
    Beresford, MJ
    Makris, A
    Taylor, NJ
    Stirling, JJ
    Ah-See, M
    d'Arcy, JA
    Collins, D
    Padhani, AR
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2005, 94 : S206 - S206
  • [28] Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI
    Chang, YC
    Huang, CS
    Liu, YJ
    Chen, JH
    Lu, YS
    Tseng, WYI
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2004, 49 (16): : 3593 - 3602
  • [29] Clinical evaluation of contrast-enhanced digital mammography and contrast enhanced tomosynthesis-Comparison to contrast-enhanced breast MRI
    Chou, Chen-Pin
    Lewin, John M.
    Chiang, Chia-Ling
    Hung, Bao-Hui
    Yang, Tsung-Lung
    Huang, Jer-Shyung
    Liao, Jia-Bin
    Pan, Huay-Ben
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2015, 84 (12) : 2501 - 2508
  • [30] Implementing the advantages of contrast-enhanced mammography and contrast-enhanced breast MRI in breast cancer staging
    Fallenberg, Eva M.
    [J]. EUROPEAN RADIOLOGY, 2024,